Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ondřej Vaněk has a total of 533 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EXPERT: A practical and forward-looking guide to capturing protein expression and purification metadata to develop machine learning models

    by Christopher D.O. Cooper, Evgeny Tankhilevich, Kim Remans, Ahmed El Marjou, Aled M. Edwards, Andrew R. Leach, Andrew Quigley, Anja Schütz, Anne Zemella, Ario de Marco, et al.

  • Open Access

    Engineering a Functional Histidine Brace Copper-Binding Site into a De Novo -Designed Protein Scaffold

    by Salvatore La Gatta, Linda Leone, Gianmattia Sgueglia, Lorena Šimunić, Yu-Kai Liao, Ondřej Vaněk, Marco Chino, Flavia Nastri, Mario Chiesa, Angela Lombardi

    De novo metalloprotein design has contributed to tremendous advances in bioinorganic chemistry by allowing the manufacturing of proteins with unique structures and functionalities that go beyond evolutionary constraints. Among the array of metal sites that can be engineered within de novo scaffolds, the design of catalytic copper centers is particularly challenging but still harder to achieve due to the versatile coordination environment and redox properties of the copper ion. Here, we present miniLPMO, a fully de novo protein, incorporating a functional histidine brace copper-binding site. Starting from a four-helix-bundle scaffold based on the designed homodimeric α2D protein, our design has integrated rational and computational strategies to optimize coordination shell residues. Circular dichroism and analytical ultracentrifugation experiments indicate that the folding and dimerization state is driven by copper binding. A detailed characterization by UV–Vis and EPR revealed that miniLPMO replicates the spectroscopic features of natural histidine brace sites. Finally, the designed metalloprotein catalyzes the cleavage of glycosidic bonds upon hydrogen peroxide activation, mimicking the activity of natural lytic polysaccharide monooxygenases (LPMOs). This study establishes the feasibility of integrating peculiar catalytic metal-binding sites into scaffolds unrelated to the native protein and designed entirely from scratch.


  • Open Access

    Fusobacterium nucleatum Lipopolysaccharides O-Antigen Defines a Novel Siglec-7 Binding Epitope

    by Cristina Di Carluccio, Ferran Nieto-Fabregat, Linda Cerofolini, Celeste Abreu, Luis Padilla-Cortés, Giulia Roxana Gheorghita, Alessandro Antonio Masi, Lorena Buono, Manasik Gumah Adam Ali, Dimitra Lamprinaki, et al.

    Fusobacterium nucleatum (Fn) is a Gram-negative bacterium predominantly found in the human oral cavity, occasionally linked to systemic diseases, including colorectal cancer. Bacterial lipopolysaccharides (LPSs) represent one of the possible virulence factors contributing to and promoting disease progression. Fn LPS is recognized by Siglec-7, a sialic acid-binding inhibitory receptor expressed on immune cells and promising novel target for cancer immunotherapy. Through a combined approach of structural biology, biophysics, NMR, and computational methods, we explored the molecular basis of the interaction between Siglec-7 and the LPS fromF. nucleatum ssp polymorphum 10953, whose O-antigen contains peculiar sugars such as the neuraminic acid and the AAT (FucpNAc4N). We discovered a novel Siglec-7 binding epitope within the LPS O-antigen repeating unit, defined by its internal sialic acid and AAT residues. We propose a wing-like movement of the O-antigen, where Siglec-7 BC and CC’ loops alternately engage the O-antigen edges within the binding site, with the BC loop forming more stable interactions. We uncover a novel Fn10953 immune evasion mechanism and highlight Siglec-7 and LPS as novel therapeutic targets for Fn-associated CRC, providing new avenues for intervention.


  • Open Access

    Molecular Basis of Siglec-7 Recognition by Neisseria meningitidis Serogroup Y CPS: Implications for Immune Evasion

    by Cristina Di Carluccio, Tania Gerpe Amor, Maria Pia Lenza, Alessandro Antonio Masi, Celeste Abreu, Viviana Longo, Francesco Albano, Ferran Nieto-Fabregat, Paola Salvatore, Geppino Falco, et al.

    Siglecs, sialic-acid-binding immunoglobulin-like lectins, are key immune cell receptors that recognize sialic acid residues on cell surfaces. Pathogens and tumor cells exploit Siglecs to evade immune responses and modulate immunity, contributing significantly to infectious disease and cancer pathogenesis. Siglec-7, primarily expressed on natural killer (NK) cells, functions as an inhibitory receptor, tightly regulating the immune activity. This study investigates the interaction between Siglec-7 and the capsular polysaccharide (CPS) of Neisseria meningitidis serogroup Y (Men-Y), a bacterium whose sialylated CPS is critical for virulence. We demonstrate that Men-Y CPS binds to inhibitory Siglec-7, potentially dampening immune recognition. We employed a multifaceted approach, combining biochemical and biophysical techniques to dissect this interaction. Enzyme-linked immunosorbent assays (ELISAs) and fluorescence titrations quantified the binding specificity and affinity. Ligand- and protein-based nuclear magnetic resonance (NMR) spectroscopy, coupled with computational modeling, provides detailed molecular insights. We highlight the critical influence of the Men-Y CPS conformation and sialic acid presentation on Siglec-7 binding. The specific arrangement of α-2,6-linked sialic acids on the CPS is crucial for Siglec-7 binding, demonstrating the importance of the CPS 3D structure. Preliminary immunological assays using stimulated U937 cells (a promonocytic cell line) further support the immunomodulatory role of Siglec-7 mediated by Men-Y CPS. These results offer valuable insights into the development of targeted therapeutic strategies against bacterial infections.


  • Multiple O- and an N-glycosylation of the stalk region of the NK cell activation receptor NKp46 mediates its interaction with the Candida glabrata epithelial adhesin 1

    by Shiva Nejadebrahim, Jana Houserová, Tomáš Ječmen, Barbora Kalousková, Celeste Abreu, Štěpán Herynek, OndřEj SkořEpa, Jan Bláha, OndřEj Vaněk


  • Insights into stability, dimerisation, and ligand binding properties of Siglec-7: Isotope labelling in HEK293 cells for protein characterisation by NMR spectroscopy

    by Celeste Abreu, Cristina Di Carluccio, Tomáš Ječmen, Ondřej Skořepa, Jan Bláha, Roberta Marchetti, Alba Silipo, Ondřej Vaněk


  • Open Access

    Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity

    by Elissa K. Leonard, Jakub Tomala, Joseph R. Gould, Michael I. Leff, Jian-Xin Lin, Peng Li, Mitchell J. Porter, Eric R. Johansen, Ladaisha Thompson, Shanelle D. Cao, et al.

    Progress in cytokine engineering is driving therapeutic translation by overcoming these proteins’ limitations as drugs. The IL-2 cytokine is a promising immune stimulant for cancer treatment but is limited by its concurrent activation of both pro-inflammatory immune effector cells and antiinflammatory regulatory T cells, toxicity at high doses, and short serum half-life. One approach to improve the selectivity, safety, and longevity of IL-2 is complexing with anti–IL-2 antibodies that bias the cytokine toward immune effector cell activation. Although this strategy shows potential in preclinical models, clinical translation of a cytokine/antibody complex is complicated by challenges in formulating a multiprotein drug and concerns regarding complex stability. Here, we introduced a versatile approach to designing intramolecularly assembled single-agent fusion proteins (immunocytokines, ICs) comprising IL-2 and a biasing anti–IL-2 antibody that directs the cytokine toward immune effector cells. We optimized IC construction and engineered the cytokine/antibody affinity to improve immune bias. We demonstrated that our IC preferentially activates and expands immune effector cells, leading to superior antitumor activity compared with natural IL-2, both alone and combined with immune checkpoint inhibitors. Moreover, therapeutic efficacy was observed without inducing toxicity. This work presents a roadmap for the design and translation of cytokine/antibody fusion proteins.


  • Open Access

    Structure of the human NK cell NKR-P1:LLT1 receptor:ligand complex reveals clustering in the immune synapse

    by Jan Bláha, Tereza Skálová, Barbora Kalousková, Ondřej Skořepa, Denis Cmunt, Valéria Grobárová, Samuel Pazicky, Edita Poláchová, Celeste Abreu, Jan Stránský, et al.

    Signaling by the human C-type lectin-like receptor, natural killer (NK) cell inhibitory receptor NKR-P1, has a critical role in many immune-related diseases and cancer. C-type lectin-like receptors have weak affinities to their ligands; therefore, setting up a comprehensive model of NKR-P1-LLT1 interactions that considers the natural state of the receptor on the cell surface is necessary to understand its functions. Here we report the crystal structures of the NKR-P1 and NKR-P1:LLT1 complexes, which provides evidence that NKR-P1 forms homodimers in an unexpected arrangement to enable LLT1 binding in two modes, bridging two LLT1 molecules. These interaction clusters are suggestive of an inhibitory immune synapse. By observing the formation of these clusters in solution using SEC-SAXS analysis, by dSTORM super-resolution microscopy on the cell surface, and by following their role in receptor signaling with freshly isolated NK cells, we show that only the ligation of both LLT1 binding interfaces leads to effective NKR-P1 inhibitory signaling. In summary, our findings collectively support a model of NKR-P1:LLT1 clustering, which allows the interacting proteins to overcome weak ligand-receptor affinity and to trigger signal transduction upon cellular contact in the immune synapse.


  • Open Access

    Protein purification strategies must consider downstream applications and individual biological characteristics

    by Kim Remans, Mario Lebendiker, Celeste Abreu, Mariano Maffei, Shaila Sellathurai, Marina M. May, Ondřej Vaněk, Ario de Marco

    Background: Proteins are used as reagents in a broad range of scientific fields. The reliability and reproducibility of experimental data will largely depend on the quality of the (recombinant) proteins and, consequently, these should undergo thorough structural and functional controls. Depending on the downstream application and the biochemical characteristics of the protein, different sets of specific features will need to be checked. Results: A number of examples, representative of recurrent issues and previously published strategies, has been reported that illustrate real cases of recombinant protein production in which careful strategy design at the start of the project combined with quality controls throughout the production process was imperative to obtain high-quality samples compatible with the planned downstream applications. Some proteins possess intrinsic properties (e.g., prone to aggregation, rich in cysteines, or a high affinity for nucleic acids) that require certain precautions during the expression and purification process. For other proteins, the downstream application might demand specific conditions, such as for proteins intended for animal use that need to be endotoxin-free. Conclusions: This review has been designed to act as a practical reference list for researchers who wish to produce and evaluate recombinant proteins with certain specific requirements or that need particular care for their preparation and storage.


  • Natural killer cell-based strategies for immunotherapy of cancer

    by Ondřej Vaněk, Barbora Kalousková, Celeste Abreu, Shiva Nejadebrahim, Ondřej Skořepa